Trial Profile

Phase 1 single-ascending dose trial of psilocybin in obese patients with steatotic liver disease

Status: Planning

Phase of Trial: Phase I

Latest Information Update: 21 Nov 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

14 Nov 2024 According to a Relmada Therapeutics media release, company expects the Phase 1 study to help define the pharmacokinetic, safety and tolerability profile of REL-P11 and, with positive data, pave the way for a Phase 2a proof-of-concept study to begin in H1 2025.
14 Nov 2024 According to a Relmada Therapeutics media release, company announced the initiation of dosing in a Phase 1 SAD study of REL-P11.
07 Aug 2024 According to a Relmada Therapeutics media release, company intends to initiate a Phase 1 study in Canada before year-end 2024.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com